Stroke

Editor's Choice

Making good decisions requires that physicians have reliable and practical data. Comparative effectiveness reviews and objective findings on different medical interventions and strategies, as provided by the Agency for Healthcare Research and Quality in its Effective Health Care Program, can help physicians make the most informed choices among treatment options.

LATEST ARTICLES

Rivaroxaban (Xarelto): A once-daily oral anticoagulant newly indicated to reduce the risk of stroke and systemic embolism in patients with atrial fibrillation

New indication: FDA approved rivaroxaban once-daily oral tablets to reduce the risk of stroke and systemic embolism in patients with nonvalvular AF.

Effective Health Care Clinician Guides

Benefit of compression stockings after stroke is modest

A roundup of information on compression stockings after stroke; quality of home INR testing; and cardiovascular risk in users of clopidogrel

Dabigatran may be a cost-effective alternative to warfarin for stroke prevention in atrial fibrillation

The recently FDA-approved oral direct thrombin inhibitor, dabigatran, may be cost-effective compared to the standard-of-care therapy of adjusted-dose warfarin in patients requiring anticoagulation for stroke prevention in atrial fibrillation, according to a pharmacoeconomic evaluation published in the Annals of Internal Medicine.

Rivaroxaban comparable to warfarin in stroke prevention

Rivaroxaban, an oral direct Factor Xa inhibitor given once daily was superior to warfarin in reducing the risk of stroke and non-central nervous system systemic embolism in patients with AF, with comparable rates of bleeding in the pre-specified on-treatment population, according to results from the ROCKET AF study.